RE Hawkins

896 total citations
29 papers, 700 citations indexed

About

RE Hawkins is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, RE Hawkins has authored 29 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in RE Hawkins's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Renal cell carcinoma treatment (7 papers) and Virus-based gene therapy research (6 papers). RE Hawkins is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Renal cell carcinoma treatment (7 papers) and Virus-based gene therapy research (6 papers). RE Hawkins collaborates with scholars based in United Kingdom, United States and Austria. RE Hawkins's co-authors include Anthony D. Long, Greg Winter, TJ Hamblin, Delin Zhu, Freda K. Stevenson, Stephen J. Russell, P A Keep, L. Robson, Kerry Chester and Richard H. J. Beǵent and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

RE Hawkins

27 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
RE Hawkins United Kingdom 14 373 226 220 192 153 29 700
R. L. Ceriani United States 12 566 1.5× 70 0.3× 457 2.1× 222 1.2× 355 2.3× 26 992
Ph. Hageman Netherlands 7 385 1.0× 64 0.3× 279 1.3× 183 1.0× 196 1.3× 10 636
Jo Ann Horowitz United States 12 364 1.0× 332 1.5× 359 1.6× 410 2.1× 70 0.5× 15 958
S A Cannistra United States 15 405 1.1× 107 0.5× 56 0.3× 324 1.7× 368 2.4× 24 1.1k
Jiahua Qian United States 17 312 0.8× 351 1.6× 162 0.7× 333 1.7× 400 2.6× 31 1.1k
Fumitaka Numa Japan 17 361 1.0× 82 0.4× 41 0.2× 165 0.9× 101 0.7× 42 800
Bart Nijmeijer Netherlands 16 318 0.9× 200 0.9× 84 0.4× 287 1.5× 134 0.9× 36 757
John McKolanis United States 12 391 1.0× 57 0.3× 168 0.8× 558 2.9× 682 4.5× 32 1.1k
Hilary Vaughan Australia 16 404 1.1× 165 0.7× 152 0.7× 178 0.9× 527 3.4× 24 926
Kouichiro Kawano Japan 17 337 0.9× 47 0.2× 73 0.3× 292 1.5× 391 2.6× 46 798

Countries citing papers authored by RE Hawkins

Since Specialization
Citations

This map shows the geographic impact of RE Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RE Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RE Hawkins more than expected).

Fields of papers citing papers by RE Hawkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RE Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RE Hawkins. The network helps show where RE Hawkins may publish in the future.

Co-authorship network of co-authors of RE Hawkins

This figure shows the co-authorship network connecting the top 25 collaborators of RE Hawkins. A scholar is included among the top collaborators of RE Hawkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RE Hawkins. RE Hawkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hawkins, RE, Sung Joon Hong, Albertas Ulys, et al.. (2009). An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 27(15_suppl). 5110–5110. 6 indexed citations
3.
4.
Gore, M., Cezary Szczylik, Camillo Porta, et al.. (2007). 4503 ORAL Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. European Journal of Cancer Supplements. 5(4). 299–299. 14 indexed citations
5.
Cohen, Roger B., Corey J. Langer, R. Katherine Alpaugh, et al.. (2006). An open label phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer. Journal of Clinical Oncology. 24(18_suppl). 3083–3083. 1 indexed citations
6.
Hawkins, RE, Ulrich Keilholz, Adam Dangoor, et al.. (2005). Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients. Journal of Clinical Oncology. 23(16_suppl). 2570–2570. 1 indexed citations
7.
Tew, Simon R., et al.. (2003). Retroviral SOX9 transduction improves re-expression of type II collagen by passaged human articular chondrocytes in 3-dimensional culture. 1 indexed citations
8.
Hawkins, RE, et al.. (1998). Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Therapy. 5(6). 770–777. 22 indexed citations
9.
Hawkins, RE, et al.. (1998). Efficient transgene regulation from a single tetracycline-controlled positive feedback regulatory system. Gene Therapy. 5(1). 76–84. 44 indexed citations
10.
Hawkins, RE, et al.. (1997). The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Therapy. 4(10). 1004–1012. 125 indexed citations
11.
Hawkins, RE, et al.. (1997). Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues. Gene Therapy. 4(9). 993–997. 27 indexed citations
12.
Hawkins, RE, et al.. (1997). Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. The Journal of Immunology. 159(12). 5889–5895. 14 indexed citations
13.
Casey, Joanne L., P A Keep, Kerry Chester, et al.. (1995). Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. Journal of Immunological Methods. 179(1). 105–116. 96 indexed citations
14.
Workman, Paul, Maurizio D’Incalci, Wilfried Bursch, et al.. (1994). New approaches in cancer pharmacology: Drug design and development (part 2). European Journal of Cancer. 30(8). 1148–1160. 16 indexed citations
15.
16.
Russell, Stephen J., Meirion B. Llewelyn, & RE Hawkins. (1992). Principles of antibody therapy.. BMJ. 305(6866). 1424–1429. 16 indexed citations
17.
Hawkins, RE, et al.. (1992). Discovery of antibodies.. BMJ. 305(6864). 1269–1272. 32 indexed citations
18.
Hawkins, RE, et al.. (1989). The prognostic significance of the half‐life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. BJOG An International Journal of Obstetrics & Gynaecology. 96(12). 1395–1399. 49 indexed citations
19.
Hawkins, RE, et al.. (1989). The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. British Journal of Cancer. 60(4). 634–637. 24 indexed citations
20.
Whorwell, Peter J., RE Hawkins, K. C. Dewbury, & Ralph Wright. (1984). Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Digestive Diseases and Sciences. 29(10). 930–933. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. L. Ceriani Breakdown of academic impact, for papers by Ph. Hageman Breakdown of academic impact, for papers by Jo Ann Horowitz Breakdown of academic impact, for papers by S A Cannistra Breakdown of academic impact, for papers by Jiahua Qian Breakdown of academic impact, for papers by Fumitaka Numa Breakdown of academic impact, for papers by Bart Nijmeijer Breakdown of academic impact, for papers by John McKolanis Breakdown of academic impact, for papers by Hilary Vaughan Breakdown of academic impact, for papers by Kouichiro Kawano
Rankless by CCL
2026